Showing 291-300 of 9526 results for "".
Bridging the Gap Between Hair Care and Skincare
https://practicaldermatology.com/topics/hair-nails/bridging-the-gap-between-hair-care-and-skincare/23800/Hair care can have an impact on scalp, face, and body skin, which demonstrates the need to consider hair care products’ intersection with the skincare category.Skin of Color Session: Dr. Harris
https://practicaldermatology.com/conferences/maui-derm-hawaii-2025/skin-of-color-session-dr-harris/32683/John E. Harris, MD, PhD, summarizes his vitiligo talk from the "Skin of Color Session" at Maui Derm 2025, during which he covered new therapeutic options for vitiligo as well as promising drugs in the pipeline and why they could be so impactful.A Biologic Test for Cutaneous Squamous Cell Carcinoma
https://practicaldermatology.com/topics/skin-cancer-photoprotection/a-biologic-test-for-cutaneous-squamous-cell-carcinoma/24025/Cutaneous squamous cell carcinoma (cSCC) encompasses a broad spectrum of disease severity, from superficial and easily treatable skin lesions to potentially life-threatening metastatic cancer. Adjuvant radiation therapy (ART) is recommended to reduce the likelihood of relapse following surgical reseChitotriosidase: Providing Confirmation of Sarcoidosis When ACE Fails
https://practicaldermatology.com/topics/clinical-case-reports/chitotriosidase-providing-confirmation-of-sarcoidosis-when-ace-fails/26642/Chitotriosidase: Providing Confirmation of Sarcoidosis When ACE FailsCannabinoid Photo-Rejuvenation: A Clinico-Pathologic Study
https://practicaldermatology.com/topics/feature/cannabinoid-photo-rejuvenation-a-clinico-pathologic-study/29188/In this study, we sought to assess the effectiveness of a novel topical formulation containing CBD isolate, resveratrol, thyme extract, caffeine, and lecithin in reversing photodamage over a 90-day treatment period.First Medication for Severe Frostbite; Biosimilar to Humira with Interchangeability Status Approved; Two Late-Stage AD Candidates Advance
https://practicaldermatology.com/series/dermwire-tv/first-medication-for-severe-frostbite-biosimilar-to-humira-with-interchangeability-status-approved-two-late-stage-ad-candidates-advance/20267/In this episode of DermWireTV, the first medication to treat severe frostbite is approved by the FDA; the first high-concentration biosimilar to Humira with interchangeability status will soon be available in the US; and two companies with late-stage atopic dermatitis candidates provide key updates.Tips for Success with Fillers
https://practicaldermatology.com/conferences/asds-2022-annual-meeting/tips-for-success-with-fillers/20149/Heidi Waldorf, MD offers tips for getting the best results possible with fillers. From how to evaluate what patients need to considering shapes and proportions, she offers hands-on advice to help achieve optimal outcomes. Plus, she discusses the importance of managing patient expectations.Identifying SCC Risk
https://practicaldermatology.com/topics/skin-cancer-photoprotection/identifying-scc-risk/20144/Sherrif Ibrahim, MD discusses the challenges of managing squamous cell carcinoma (SCC). Great steps have been made in clinical, pathological staging systems, but Dr. Ibrahim says it’s still difficult to determine what to do with borderline cases. He talks about the need to determine frequency and inUnderstanding and Addressing the Impact of Plaque Psoriasis Among Patients with Skin of Color
https://practicaldermatology.com/topics/psoriasis/understanding-and-addressing-the-impact-of-plaque-psoriasis-among-patients-with-skin-of-color/23763/Patients, physicians, and others are joining together to elevate the level of care for patients with skin of color who develop psoriatic disease.DermWireTV: Zoryve Approved; New SDPA President; Project Determi-Nation; Stelara for Pediatric PsA
https://practicaldermatology.com/topics/psoriasis/dermwiretv-zoryve-approved-new-sdpa-president-project-determi-nation-stelara-for-pediatric-psa/20115/FDA has approved Zoryve from Arcutis Biotherapeutics for the treatment of plaque psoriasis, including intertriginous areas, in patients 12 years of age or older. The novel formulation of roflumilast cream 0.3% is indicated for once-daily application. Stelara (ustekinumab) from Janssen is now approve